Pharmaceuticals 14 January 2026

Pfizer stock edges higher as vaccine-policy jitters and obesity race frame the next catalyst

Pfizer shares edged up roughly 0.3% to $25.67 on Thursday, finding footing after a volatile start to the year. Investors mulled over renewed discussions on U.S. vaccine policy alongside Pfizer’s growth strategy. The stock fluctuated between $25.26 and $25.67, with about 22.3 million shares changing hands.

15 January 2026

NASDAQ:GPCR·NYSE:PFE·NYSE:SNY·Pharmaceuticals·Stock Market

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock.

15 January 2026

NASDAQ:GP·NASDAQ:MRNA·NYSE:LLY·NYSE:MRK·NYSE:NVO·NYSE:PFE·NYSE:SNY·Pharmaceuticals·Stock Market

AbbVie stock slides 2% as obesity push takes center stage at JPM conference

AbbVie shares dropped 2.1% to $217.13 Thursday following the company’s expanded plans for obesity treatments announced at the J.P. Morgan Healthcare Conference.

15 January 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

Johnson & Johnson stock slips as Tecvayli trial data lands ahead of earnings week

Johnson & Johnson shares dipped Thursday following fresh late-stage data release for its Tecvayli cancer drug, with investors also bracing for next week’s earnings report.

15 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceuticals·Stock Market

GSK stock rises as pipeline talk hits JPM conference, with Feb. 4 earnings in focus

GSK plc’s shares traded in the U.S. climbed 1.8% on Wednesday, closing at $50.79. The stock remains in the spotlight heading into Thursday’s session.

15 January 2026

Earnings Reports·LSE:GSK·NYSE:GSK·Pharmaceuticals·Stock Market

Merck stock rises as $70 billion growth target sharpens focus ahead of Feb. 3 earnings

Merck & Co shares closed Wednesday up 2.54% at $111.01, rebounding from a short dip and holding close to recent peaks ahead of Thursday’s trading.

15 January 2026

Earnings Reports·NYSE:MRK·Pharmaceuticals·Stock Market

AbbVie stock in focus after hours as it eyes obesity market — what to watch next

AbbVie Inc’s shares climbed roughly 0.5% to $221.89 in after-hours trading Wednesday, following executives’ announcement to expand the company’s footprint in obesity treatments. During the regular session, the stock fluctuated between $217.84 and $223.27.

15 January 2026

NYSE:ABBV·Pharmaceuticals·Stock Market

Pfizer stock rises as CEO bets on “Viagra-like” obesity demand; what investors watch next

Shares of Pfizer climbed Wednesday as investors focused on the company’s move into obesity treatments, now the key battleground in the pharmaceutical sector.

15 January 2026

NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment.

15 January 2026

NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson stock rises after Tecvayli trial win as JNJ eyes earnings

Johnson & Johnson shares climbed 2.3% to $218.55 in after-hours trading Wednesday following upbeat topline data from a late-stage multiple myeloma study for Tecvayli.

15 January 2026

Earnings Reports·NYSE:JNJ·Pharmaceuticals·Stock Market

Pfizer (PFE) stock rises as CEO calls obesity push a “Viagra”-scale bet, with earnings next in focus

Pfizer Inc shares climbed about 2% to $25.65 on Wednesday following CEO Albert Bourla’s remarks on the company’s push into the rapidly expanding cash-pay obesity drug market. “We are all in on obesity,” Bourla told reporters at the J.P. Morgan Healthcare Conference. Pfizer plans to launch 10 Phase 3 trials for its Metsera obesity compounds by the end of 2026, aiming to fuel future growth. The company still doesn’t expect revenue growth to return until 2029, as it navigates patent expirations and a slowdown in COVID-era sales.

14 January 2026

Earnings Reports·NYSE:PFE·Pharmaceuticals·Stock Market

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak.

14 January 2026

Biotechnology·NASDAQ:VRDN·Pharmaceuticals

Nuvalent stock jumps as FDA review clock sharpens focus on 2026 launch plans

Nuvalent’s stock climbed roughly 6% Wednesday afternoon, building on earlier gains as the biotech detailed crucial 2026 goals for its lead lung-cancer project and highlighted a sizable cash pile expected at year-end.

14 January 2026

NASDAQ:NUVL·Pharmaceuticals·Stock Market

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Shares of Structure Therapeutics jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares.

14 January 2026

NASDAQ:GPCR·NASDAQ:TERN·NASDAQ:VKTX·NYSE:LLY·NYSE:NVO·Pharmaceuticals·Stock Market

Terns Pharmaceuticals stock jumps 10% as JPM conference puts TERN-701 back on the map

Terns Pharmaceuticals shares jumped over 10% Wednesday, fueled by the company’s newest conference update on its lead cancer drug. By midday, the stock had risen 10.4% to $38.03, after trading in a range from $34.05 to $38.35.

14 January 2026

Biotechnology·NASDAQ:TERN.O·Pharmaceuticals

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID.

14 January 2026

Earnings Reports·NYSE:LLY·NYSE:NVO·NYSE:PFE·Pharmaceuticals·Stock Market

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning.

14 January 2026

Earnings Reports·NYSE:LLY·Pharmaceuticals·Stock Market

Johnson & Johnson stock rises on Auris court win as talc fight and Jan. 21 earnings loom

Johnson & Johnson shares climbed 1.9% to $217.80 by late morning Wednesday, defying the SPDR S&P 500 ETF, which dipped roughly 1%.

14 January 2026

Earnings Reports·NYSE:ABBV·NYSE:JNJ·NYSE:MRK·NYSE:PFE·Pharmaceuticals·Stock Market

Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS

Gelteq Limited shares surged roughly 48% to $1.23 in premarket action Wednesday, following a 6.4% gain at Tuesday’s close.

14 January 2026

NASDAQ:GELS·Pharmaceuticals·Stock Market

NRXP stock slips premarket as NRx says FDA fast-tracked ketamine bid with 70,000-patient dataset

NRx Pharmaceuticals shares dropped 4.3% to $2.13 in premarket on Wednesday. The FDA granted Fast Track status to NRX-100, the company’s preservative-free ketamine treatment targeting suicidal ideation. NRx plans to submit real-world data from over 70,000 patients to back an accelerated approval application. CEO Jonathan Javitt noted, “An American commits suicide every 11 minutes.”

14 January 2026

NASDAQ:NRXP·Pharmaceuticals·Stock Market

Pharmaceuticals 14 January 2026 - 15 January 2026